A study of ASP2151 in subjects with recurrent outbreaks of genital herpes.
Official Title
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes.
Conditions
- Herpes Genitalis
Study Type
Interventional
Study Design
Treatment, Randomised, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study.
Further Details
Primary Outcome Measures:
- To compare the efficacy and safety of ASP2151 with valacyclovir and placebo in the acute treatment of recurrent genital Herpes Simplex Virus Infection
Secondary Outcome Measures:
- Pharmacokinetics in study patients
For more infomation visit Clinicaltrials.gov
Study Start
June 2007
Eligibility & Criteria
- Ages Eligible for Study: 18 Years and older
- Genders Eligible for Study: Both
- Accepts Healthy Volunteers: No
Inclusion Criteria:
- History of genital HSV documented by laboratory testing at screening
- 4 or more episodes of genital herpes during the past 12 months
Exclusion Criteria:
- Subject is immunocompromised
Total Enrolment
Estimated to be 650
Contact Details
Please refer to this study by its ClinicalTrials.gov identifier: NCT00486200
Contact:
Astellas Pharma US Medical Information
Phone number: 800-727-7003
Email: clintrials.info@us.astellas.com
All content and media on the HealthEngine Blog is created and published online for informational purposes only. It is not intended to be a substitute for professional medical advice and should not be relied on as health or personal advice. Always seek the guidance of your doctor or other qualified health professional with any questions you may have regarding your health or a medical condition. Never disregard the advice of a medical professional, or delay in seeking it because of something you have read on this Website. If you think you may have a medical emergency, call your doctor, go to the nearest hospital emergency department, or call the emergency services immediately.